First ROXUS Prescriptions Fulfilled in the United States
Released
Released
Announcement PDF
1800 519 711 | ltrpharma.com | investors@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
First ROXUS®
Prescriptions Fulfilled in the United States
06 October 2026
Highlights
• First patient-specific ROXUS®
prescriptions received through Mavrox, Shed’s men’s health telehealth
platform, have now been fulfilled in the United States.
• Mavrox provides the initial U.S. direct-to-consumer telehealth route for ROXUS, with Strive Pharmacy
supporting prescription compounding and fulfilment.
• LTR Pharma will now focus on supporting its U.S. partners as prescribing and prescription activity builds.
LTR Pharma Limited (ASX: LTP) (“LTR Pharma” or “the Company”) is pleased to announce that the first patient-
specific ROXUS®
prescriptions received through Mavrox, Shed’s men’s health telehealth platform, have now been
fulfilled in the United States.
The milestone marks the commencement of ROXUS prescription activity through the telehealth and pharmacy
arrangements established under LTR Pharma’s agreements with Shed and Strive Pharmacy.
The first prescriptions follow completion of the operational work required to support ROXUS prescription
fulfilment in the United States.
ROXUS is LTR Pharma’s intranasal medication for erectile dysfunction support, compounded and dispensed in the
United States by a licensed pharmacy under the patient-specific compounding provisions of Section 503A of the
US Federal Food, Drug, and Cosmetic Act.
U.S. Prescription Fulfilment
Strive Pharmacy has established the operational systems required to receive, compound and fulfil valid patient-
specific ROXUS prescriptions.
LTR Pharma Executive Chairman, Lee Rodne, said:
“Fulfilment of the first ROXUS prescriptions in the United States is an important milestone for LTR Pharma and
our US partners.
With our first prescriptions now received through Mavrox, we have moved from implementation to serving
patients under these arrangements. Our focus is now on supporting our partners as prescribing and prescription
activity builds.
This milestone comes less than three months after we announced our agreement with Shed to establish a U.S.
telehealth route to patients.”
1800 519 711 | ltrpharma.com | investors@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
Next Steps
LTR Pharma will continue working with Shed and Strive Pharmacy to support ROXUS prescription fulfilment
through Mavrox. The Company will provide further updates on US prescription activity as meaningful information
becomes available.
ROXUS is a compounded medication prepared for identified individual patient needs based on a valid prescription
from a prescribing healthcare practitioner and, as such, is not reviewed or approved by the U.S. Food and Drug
Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has
determined their medical needs are not met by an available FDA-approved drug. These statements have not been
evaluated by the FDA. Prescribers should use their independent clinical judgement when determining
appropriateness for individual patients.
– ENDS –
This announcement has been authorised for release by the Board of LTR Pharma Limited.
Forward-looking statement
This announcement contains forward-looking statements, including in relation to ongoing US prescription activity
and prescription fulfilment. These statements involve risks and assumptions beyond the Company’s control, and
actual results may differ materially. The Company does not undertake to update any forward-looking statement
except as required by law.
About LTR Pharma
LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant
unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully
commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing
regulatory pathways in the US and other key markets.
LTR’s lead products, SPONTAN®
and ROXUS®
, are fast-acting intranasal sprays for the treatment of erectile
dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is
now advancing OROFLOW®
, a novel intranasal spray under development for the treatment of Oesophageal
Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.
Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated,
patient-centric treatments that enhance quality of life.
1800 519 711 | ltrpharma.com | investors@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
LTR Pharma Investor Centre
Stay informed with LTR Pharma’s latest announcements and
market updates by visiting our Investor Centre or scan the QR code.
For further information please contact:
Media enquiries Investor enquiries
Haley Chartres Peter McLennan
haley@hck.digital investors@ltrpharma.com
Share your feedback
Discover